Fascinating results from Nadia Pillai, using real world data from a Swiss IBD cohort to model the cost-effectiveness of early biologic therapy. Early use of biologics is not cost effective in this cohort, but this outcome changes with biologic price drops or with more careful patient selection.

Claire Liefferinckx discusses her work with the Belgian Inflammatory Bowel Disease research and development group (BIRD) to capture real-world outcomes of ustekinumab treatment for Crohn’s disease, using a large national cohort of patients with a history of significant previous biologic exposure.